证券代码：301069 证券简称：凯盛新材 公告编号：2023-047 山东凯盛新材料股份有限公司 关于部分募集资金专户完成销户的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、募集资金基本情况 经中国证券监督管理委员会 2021 年 8 月 10 日下发的《关于同意山东凯盛 新材料股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕2626 号），同意公司首次公开发行人民币普通股（A 股）股票 6,000 万股，每股面值 1 元，每股发行价格为人民币 5.17 元，募集资金总额人民币 31,020.00 万元， 扣除与发行有关的费用（不含增值税）人民币 2,830.85 万元，公司实际募集资 金净额为人民币 28,189.15 万元。公司募集资金已于 2021 年 9 月 22 日到账， 四川华信（集团）会计师事务所（特殊普通合伙）对公司首次公开发行股票的 资金到位情况进行了审验，并于 2021 年 9 月 22 日出具了川华信验（2021）第 0076 号《验资报告》。 二、募集资金三方监管协议的签订和募集资金专户的开立情况 ...

证券代码：301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 编号：20230517 特定对象调研 分析师会议 媒体采访 业绩说明会 投资者关系 新闻发布会 路演活动 活动类别 现场参观 其他 参与单位名称 及人员姓名 详见附件一：《参与单位名称及人员姓名明细表》 时 间 2023 年 5 月 17 日（周三） 15:00-17:00 地 点 线上：易董 APP/腾讯会议 孙庆民(董事、总经理） 上市公司接 王荣海（董事、副总经理、董事会秘书） 待人员姓名 王 赞（财务经理） 杨紫光（证券事务代表） 一、公司 2022 年度及 2023 年第一季度经营情况介绍 投资者关系 2022 年度，在全球经济下行的大环境下，部分下游行业面临着需求阶 段性收缩等不利形势。公司管理层充分发挥公司产线弹性大的优势，及时 活动主要内 结合市场新需求调整产品结构，在氯化产业链上优存量、筑增量，在保证 容介绍 氯化亚砜等基础产品出货量的前提下，以芳纶聚合单体、氯乙酰氯等新市 场需求对冲部分产品需求阶段性下滑的市场风险，稳住现有国际市场，积 1 极开拓国内市场，最终实现各项经济运行指标稳步增长。2022 ...

证券代码： 301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 编号：20230516 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | 新闻发布会 路演活动 □ □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 16 日 (周二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事、总经理：孙庆民 | | 员姓名 | 2、董事、副总经理、董事会秘书：王荣海 | | | 3、独立董事：朱清滨 | | | 4、副总经理、财务总监：杨善国 | | | 5、保荐代表人：孔辉焕 投资者提出的问题及公司回复情况 | | | 1、领导下午好！请问公司关于股权激励方面有没什么新的进 | | | 公司就投资者在本次 ...

证券代码：301069 证券简称：凯盛新材 公告编号：2023-036 山东凯盛新材料股份有限公司 关于召开2022年年度报告业绩网上说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、会议召开情况 山东凯盛新材料股份有限公司（以下简称"公司"）将于 2023 年 5 月 16 日（星 期二）下午 15:00-17:00 在"全景网"提供的平台举行《2022 年年度报告》网上业 绩说明会，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与 本次说明会。公司《2022 年年度报告》及其摘要已刊登在《中国证券报》、《证 券时报》、《证券日报》、《上海证券报》和巨潮资讯网（www.cninfo.com.cn），敬 请投资者查阅。 二、参会人员 出席本次年度报告业绩网上说明会的人员包括： 4、杨善国先生（财务总监） 5、孔辉焕先生（保荐代表人） 欢迎广大投资者积极参与本次业绩说明会！ 三、问题征集 投资者可扫描下方二维码预先提出问题： - 1 - 1、孙庆民先生（董事、总经理） 2、王荣海先生（董事、董事会秘书 ...

Financial Performance - The company's revenue for Q1 2023 was ¥248,028,189.67, a decrease of 3.82% compared to ¥257,889,942.36 in the same period last year[5] - Net profit attributable to shareholders was ¥50,672,203.78, down 26.39% from ¥68,837,886.38 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 248,028,189.67, a decrease of 3.34% compared to CNY 257,889,942.36 in Q1 2022[22] - Net profit for Q1 2023 was CNY 50,609,357.55, down 26.54% from CNY 68,837,886.38 in the same period last year[23] - The total comprehensive income for Q1 2023 was ¥50,609,357.55, down from ¥68,837,886.38 in Q1 2022[24] Cash Flow - The net cash flow from operating activities was -¥53,679,767.28, representing a decline of 109.97% compared to -¥25,565,492.63 in the previous year[5] - Cash inflow from operating activities totaled ¥96,333,280.23, a decline of 13.3% from ¥111,051,731.17 in Q1 2022[26] - Cash and cash equivalents at the end of Q1 2023 were ¥172,357,639.45, down from ¥303,024,322.61 at the end of Q1 2022, representing a decrease of 43.1%[28] - The company reported cash outflows from investing activities of ¥191,577,216.61, compared to ¥401,722,911.91 in the previous year, indicating a significant reduction in investment spending[27] - The net cash flow from investing activities was -¥16,254,776.14, contrasting with a positive cash flow of ¥128,024,770.41 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.95% to ¥1,717,809,048.67 from ¥1,668,525,610.49 at the end of the previous year[5] - Accounts receivable rose to CNY 93,194,426.32, an increase of 25.49% from CNY 74,257,599.33 at the beginning of the year[20] - Cash and cash equivalents decreased to CNY 172,357,639.45 from CNY 242,320,450.51, a decline of 28.83%[20] - Inventory increased to CNY 54,553,932.35, up 28.43% from CNY 42,504,525.44 at the beginning of the year[20] - Total liabilities remained relatively stable at CNY 247,682,415.89, compared to CNY 247,635,312.42 at the beginning of the year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,470, with the largest shareholder holding 44.51% of the shares[14] - Major shareholders include Huabang Life Health with 187,216,000 shares and CITIC Securities with 13,712,000 shares, all classified as pre-IPO restricted shares[17] - The total number of restricted shares at the beginning of the period was 280,200,000, with no new restrictions added during the quarter[17] - The top ten unrestricted shareholders hold a total of 18,193,600 shares, with Hongxin Guotai (Beijing) Investment Co., Ltd. being the largest[15] - The total number of unrestricted shares held by the top ten shareholders is 18,193,600, representing a significant portion of the company's equity[15] Expenses - Total operating costs increased to CNY 189,232,030.29 from CNY 178,678,210.88, reflecting a rise of 5.77%[23] - Research and development expenses increased by 53.60% to ¥1,430,000.00, reflecting the company's commitment to innovation[11] - Management expenses rose by 51.92% to ¥1,600,000.00, primarily due to increased equity incentive costs and depreciation[11] - Research and development expenses for Q1 2023 were CNY 14,307,857.49, compared to CNY 9,314,962.01 in Q1 2022, marking a 53.06% increase[23] Share Performance - The company's weighted average return on equity decreased to 3.51% from 5.26% year-on-year[5] - The basic and diluted earnings per share for Q1 2023 were both ¥0.1205, down from ¥0.1637 in the same period last year[24] Investment Income - The company experienced a 44.67% decrease in investment income, down ¥483,900.00, attributed to reduced returns from financial investments[11] - The company reported a 30.27% decrease in trading financial assets, down ¥64,726,500.00, due to reduced investment holdings to meet operational funding needs[10] Other Information - The company has not disclosed any new strategies or market expansions in the current report[18] - The company has not reported any new product developments or technological advancements in this quarter[18] - The company has no new developments or changes in the number of preferred shareholders during the quarter[16] - There are no changes in the number of restricted shares for major shareholders during the quarter[17] - The report indicates that the release date for restricted shares is set for September 27, 2024[17] - The company did not report any audited financial results for the first quarter[29]

Financial Performance - The company's operating revenue for 2022 was CNY 1,010,484,930, representing a 14.88% increase compared to CNY 879,591,549 in 2021[20] - The net profit attributable to shareholders for 2022 was CNY 234,523,025, a 21.28% increase from CNY 193,379,072 in the previous year[20] - The net profit after deducting non-recurring gains and losses was CNY 226,421,389, which is a 25.95% increase from CNY 179,772,058 in 2021[20] - The total assets at the end of 2022 amounted to CNY 1,668,525,610, reflecting a 17.29% increase from CNY 1,422,613,681 at the end of 2021[20] - The basic earnings per share for 2022 was CNY 0.5575, an increase of 8.29% compared to CNY 0.5148 in 2021[20] - The company reported a total of 8,101,636.32 yuan in non-recurring gains and losses for 2022, a decrease from 13,607,013.54 yuan in 2021, indicating a decline of approximately 40.5%[26] - The company reported a gross profit margin of 39.02% for the chemical new materials sector, an increase of 2.24% compared to the previous year[63] - The company reported a significant increase in user data, reflecting a growing customer base and market demand for its products[126] Cash Flow and Investments - The cash flow from operating activities showed a significant decline, with a net outflow of CNY 10,444,069, down 88.22% from CNY 88,631,424 in the previous year[20] - Operating cash inflow totaled ¥548,206,165.34 in 2022, a 12.66% increase compared to ¥486,598,692.60 in 2021[76] - The net cash flow from operating activities decreased by 88.22% to ¥10,444,069.03, primarily due to increased construction and equipment payments[76] - Investment cash inflow surged by 212.75% to ¥2,158,855,085.36, compared to ¥690,287,142.33 in 2021[76] - The total investment amount for the reporting period was ¥16,195,665.20, reflecting a 54.24% increase compared to the previous year's investment of ¥10,500,000.00[82] - The company raised a total of CNY 31,020.00 million through the issuance of 60 million shares, with a net amount of CNY 28,189.15 million after expenses[89] - The company has committed to invest CNY 23,189.15 million in a 2,000 tons/year polyether ketone resin project, with 100% of the investment completed by November 30, 2022[91] Research and Development - The company’s R&D strategy is aligned with national innovation-driven development, focusing on market trends and customer needs to drive product innovation[32] - The company has a strong technical foundation with over 139 patents, including 88 invention patents, and a research team of 204 personnel, enhancing its competitive edge in the chemical industry[36] - The company is developing an automated distillation process for acyl chloride products, aiming to improve efficiency and reduce production costs[71] - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability[182] - The number of R&D personnel increased by 33.33% from 153 in 2021 to 204 in 2022, with a proportion of 27.27% of total employees[74] Production and Capacity - Chlorinated steel production capacity is designed at 150,000 tons/year with a utilization rate of 94.24%[46] - The production capacity for isophthaloyl chloride is 31,000 tons/year with a utilization rate of 76.31%, and a new project of 20,000 tons/year is under construction[46] - The production capacity for PEKK is 100 tons/year with a utilization rate of 11.00%, and an additional 1,000 tons/year production facility is currently in trial production[46] - The company is actively expanding its production capacity, with a new chlorinated acetyl chloride project entering trial production in February 2023[47] Market and Sales - The company’s overseas sales revenue accounted for 13.80% of total operating income in 2022, indicating a strong presence in international markets[34] - Domestic sales reached CNY 871,079,880.70, making up 86.20% of total revenue, while international sales surged by 127.11% to CNY 139,405,049.30[61] - The chemical new materials segment contributed CNY 982,438,338.15, accounting for 97.22% of total revenue, with a year-on-year growth of 12.43%[60] Governance and Compliance - The company has maintained a consistent governance structure, with independent directors ensuring compliance and oversight[130] - The company established an internal control system to ensure compliance with laws and regulations, enhancing operational management and risk control[113] - The company has no significant discrepancies in governance compared to regulations set by the China Securities Regulatory Commission[116] - The company held one annual and two temporary shareholder meetings during the reporting period, ensuring compliance with legal requirements[110] Environmental and Safety Management - The company has established a comprehensive safety and environmental management system, ensuring stable operations through regular safety training and inspections[37] - The company is committed to technological innovation, focusing on the recycling and utilization of sulfur dioxide, contributing to a green economy[38] - The company has implemented a comprehensive environmental monitoring plan, ensuring compliance with discharge standards[163] - The company has established an emergency response plan for environmental incidents, enhancing its ability to prevent and manage such events[162] Employee and Management - The total remuneration for directors, supervisors, and senior management in 2022 amounted to CNY 6.8025 million, reflecting a performance-based compensation structure[132] - The company has a clear remuneration policy linked to performance, ensuring alignment of interests between management and shareholders[131] - The company plans to enhance employee training programs in 2023, focusing on operational management and skill development to improve overall competitiveness[143] Strategic Outlook - The company aims to achieve a revenue growth target of 15% by 2025, indicating a strong outlook for future performance[124] - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 500 million RMB allocated for this purpose[181] - The company is committed to maintaining compliance with regulatory standards to avoid any potential legal issues related to its operations[181]

编号：20211102 证券代码：301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 分析师会议 | | 投资者关系 | 业绩说明会 | | 活动类别 | 路演活动 | | | | | | | | | 海通证券、东方证券、中泰证券、天风证券、广发证券、国元证 | | 参与单位名称 及人员姓名 | 券、西南证券、西部证券、国泰君安证券、华金证券、平安资产、 睿远基金、大朴资产、中庚基金、中海基金、大成基金、中欧基 金、上投摩根基金、东证资管、上海瑞杨投资、混沌投资、西安 | | | 瀑布资产管理有限公司、青岛朋元资产管理有限公司 | ...

编号：20220516 证券代码：301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------------|----------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | | | 南方基金、混沌资产、富国基金、中欧基金、工银瑞信、易方达基金、 | | 参与单位名称及 | | 宝盈基金、盘京投资、交银施罗德、兴业基金、汇丰晋信、华安基金、 | | 人员姓名 | | 天弘基金、长城基金、融通基金、国海富兰克林、长江养老保险、申 | | | | 万菱信基金、圆信永丰、源乐晟招银理财、恒睿信投资、丰奘投资 | | 时间 | 2022 年 5 月 9 日-5 月 | 14 日 | | 地点 | | 线上（腾讯 ...

证券代码：301069 证券简称：凯盛新材 公告编号：2022-042 山东凯盛新材料股份有限公司 关于参加山东辖区上市公司2022年度投资者网上 集体接待日活动的通知公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步做好投资者关系管理工作，增强与广大投资者的互动交流，山东凯 盛新材料股份有限公司（以下简称"公司"）将参加由山东证监局、山东上市公 司协会联合深圳市全景网络有限公司举办的"山东辖区上市公司 2022 年度投资 者网上集体接待日活动"（以下简称"本次活动"），现将有关事项公告如下： 1. 本次活动的时间：2022 年 11 月 16 日（星期三）下午 14:00-16:00。 2. 本次活动的交流网址：本次活动将通过深圳市全景网络有限公司提供的 网上平台，采取网络远程的方式进行，投资者可以登陆全景网"全景·路演天下" （http://rs.p5w.net）进入专区页面参与交流。 3. 公司出席本次活动的相关人员： （1）王荣海先生（董事、副总经理、董事会秘书） （2）杨善国先生（副总经理、财务总监） 4. 届时以上公司领导将通过网络在线交流 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 399,443,228.84, representing a 31.05% increase compared to the same period last year[27]. - The net profit attributable to shareholders of the listed company was CNY 94,965,761.61, reflecting a growth of 38.27% year-on-year[27]. - The net profit after deducting non-recurring gains and losses was CNY 92,250,317.16, which is a 35.11% increase compared to the previous year[27]. - The basic earnings per share increased by 18.57% to CNY 0.2633[27]. - The company's operating revenue for the current period reached ¥523,488,303.52, representing a year-on-year increase of 31.05% due to higher product prices and increased sales volume of aramid polymer monomers[50]. - The total operating revenue for the first half of 2022 was CNY 523,488,303.52, an increase from CNY 399,443,228.84 in the same period of 2021, representing a growth of approximately 31.1%[188]. - The company's net profit for the first half of 2022 was CNY 131,313,607.79, an increase of 38.2% compared to CNY 94,965,761.61 in the same period of 2021[195]. - The company's operating profit was CNY 159,898,623.89, compared to CNY 114,208,982.04 in the prior year, reflecting a growth of 40.0%[199]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,422,613,681.07, up 5.20% from the end of the previous year[27]. - The total assets as of June 30, 2022, amounted to CNY 1,457,460,160.04, compared to CNY 1,422,037,260.76 at the beginning of the year, reflecting a growth of approximately 2.5%[188]. - The total liabilities as of June 30, 2022, were CNY 128,699,863.40, slightly up from CNY 127,937,913.55 at the beginning of the year[188]. - The company's total liabilities included accounts payable of ¥147,417,319.04, which increased from ¥99,106,607.54, indicating a rise of approximately 48.7%[179]. Cash Flow - The net cash flow from operating activities decreased significantly by 149.55% to CNY 34,399,917.53[27]. - The net cash flow from operating activities was -¥17,046,096.74, a significant decrease of 149.55% compared to the previous year, influenced by increased cash payments for goods procurement[50]. - The company's cash and cash equivalents increased by 246.87% to ¥47,964,744.26, mainly due to net redemptions of financial products based on operational funding needs[50]. - The cash and cash equivalents increased to CNY 244,491,708.32 from CNY 196,298,048.84, marking a rise of approximately 24.5%[185]. Research and Development - Research and development expenses increased by 14.70% to ¥18,405,730.82, mainly due to rising prices of bulk raw materials and energy[50]. - Research and development expenses increased to CNY 18,405,730.82, representing a rise of 14.7% from CNY 16,046,200.44 in the previous year[196]. - The company holds 137 valid patents, including 86 invention patents, and has established various innovation platforms such as a national postdoctoral research station and a national enterprise technology center[43]. Environmental and Safety Management - The company emphasizes safety and environmental management, ensuring stable operations through rigorous safety training and compliance with production standards[38]. - The company has implemented a wastewater treatment system that meets the standards of GB31573-2015 and GB/T31962-2015, ensuring compliance with discharge regulations[102]. - The average concentration of COD in wastewater is 40.7 mg/L, and ammonia nitrogen is 2.36 mg/L, both below the allowable limits of 500 mg/L for COD and 45 mg/L for ammonia nitrogen[99]. - The company has established dedicated departments for safety and environmental management to ensure compliance with regulations[85]. - The company has enhanced its environmental protection efforts, ensuring all pollutants met discharge standards during the reporting period[116]. Strategic Initiatives - The company has formed a development strategy that extends from fine chemicals to high-performance polymer materials, enhancing overall competitiveness[45]. - The company has implemented a core technology for the separation and recycling of sulfur dioxide, reducing production costs and addressing environmental concerns[44]. - The company has established stable relationships with high-quality customers, including major aramid producers like DuPont, Teijin, and Kolon[47]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company held its annual general meeting on April 8, 2022, with a participation rate of 74.89%[90]. - The company approved a restricted stock incentive plan on April 11, 2022, proposing to grant a total of 2.176 million shares, with 1.976 million shares allocated to 201 incentive recipients and 200,000 shares reserved[95]. - The total number of shares is 420,640,000, with 360,640,000 shares subject to restrictions, representing 85.74%[149]. Risks and Challenges - The company faces significant risks from raw material price fluctuations, as raw materials account for a large proportion of the main business costs, impacting gross margins[81]. - Environmental policy risks are increasing, with potential additional investments required to meet stricter regulations, which could raise operational costs[85]. - The company anticipates potential increases in production costs due to energy substitution policies, but has prepared by building a natural gas boiler as a backup[86]. Community Engagement - The company donated RMB 1 million and over RMB 50,000 worth of protective materials to support local pandemic prevention efforts[113].